PubMed Health⌕ Search

Biomedical subjects

F Edsmyr

Publications and source records attributed to F Edsmyr.

At least 55 records · Page 3Linked to original sources
PubMed1980

External irradiation therapy in carcinoma of the prostate.

107 patients with poorly differentiated prostatic carcinoma without metastases received local irradiation at the Karolinska Hospital from 1965 through 1973. The majority of the patients had received previous hormone therapy and had a progressive local disease. Many of them were given estrogens even after radiotherapy. All the patients were followed for at least 5 years. Complete regression of the palpable prostatic carcinoma mass was registered in about 70% of the cases. A 33% 5-year survival was obtained. This is significantly higher than the survival of the comparable group of patients receiving only hormones.

Aged↗
PubMed1980

Intravesical instillation of Adriamycin. A model for standardization of the chemotherapy.

Intravesical instillation of Adriamycin has successfully been used in the treatment of bladder tumours. The Adriamycin concentration in the bladder has been monitored and the area under the bladder concentration-time curve, AUC, is proposed to be considered rather than the amount of instilled drug when optimizing the treatment schedules. pH effects which may arise in the bladder when instilling protolytic drugs like Adriamycin are discussed.

Doxorubicin↗
PubMed1980

Changes of the blood lymphocyte population in cancer patients treated with bestatin, a new immunomodulator. A phase I study.

Twenty one patients with advanced metastatic cancer of various types received 30 mg of Bestatin daily per os as a single treatment for several weeks. It was observed that the blood lymphocyte counts remained unchanged but the frequency of SRBC rosette forming cells increased and the frequency of lymphocytes possessing receptors for the Fc-part of IgG became normalized after two weeks of treatment. The frequency of lymphocytes possessing receptors for C'3 was not changed. The natural killer activity of peripheral lymphocytes for K562 and Chang cells increased but the PPD stimulation of the lymphocytes was not altered. A slight, but significant increase of the PHA stimulation of lymphocytes was observed after 4-7 weeks of Bestatin treatment. It is concluded that Bestatin is a nontoxic drug which changes the cellular composition as well as certain immunological functions of human lymphocytes.

Adult↗
PubMed1979

Possible tumour markers in patients with oesophagus cancer.

Carcinoembryonic antigen (CEA), alpha-foetoprotein (AFP), and enzymes were determined in the blood of 59 patients with primary oesophagus carcinoma. Raised CEA values were encountered in 59% of the patients, and AFP above that of an age-matched control group in 33% of the patients. Values of CEA during progression were significantly higher than in regression of disease. Two patients had exceptionally high serum AFP, but in most cases AFP levels were not related to disease progress. CEA and AFP could appear in a discordant fashion. The combined assay did not improve diagnostic sensitivity.

Adenocarcinoma↗
PubMed1978

Blood coagulation studies in patients with advanced carcinoma of the prostate treated with 2,6-cis-diphenylhexamethylcyclotetrasiloxane or estramustine-17-phosphate.

Two drugs, 2,6-cis-diphenylhexamethylcyclotetrasiloxane (Cisobitan) and estramustine-17-phosphate (Estracyt) were given to patients with poorly differentiated metastatic carcinoma of the prostate. The effect of the drugs on blood coagulation was investigated. Some parameters showed changes during the treatment: Antithrombin III decreased in the Estracyt treated patients to a level which might imply a thrombogenic effect. Fibrinogen decreased, whereas factor VIII showed no consistent change. Normotest changes appeared to correlate with liver damage whereas antithrombin III showed no change. Increased levels of fibrinogen degradation products and fibrinopeptide A (FPA) were more frequent in the group of deteriorating patients. However, the number of FPA analyses were too small for any definite conclusions regarding possible disseminated intravascular coagulation.

Afibrinogenemia↗
PubMed1978

The role of exfoliative cytology in the management of bladder carcinoma.

Cytological analyses of bladder washings from 974 patients with disorders of the urinary tract are reported. The cytological findings were compared with the clinical and histological diagnoses. The histological grading of bladder tumours was based on the classification proposed by Bergkvist et al. No false positive diagnosis of malignancy was made in the 320 patients without tumour growth. The five cases with positive cytology had histologically verified carcinoma in situ. The frequency of cytological diagnosis of cancer increased with the histological grade of malignancy in the 428 patients with bladder neoplasm. Carcinoma was graded in smears according mainly to the degree of epithelial atypia. A comparison with the histological grading was attempted. Of 226 cases of bladder carcinoma treated with supervoltage irradiation, 108 had persistence or recurrence of carcinoma. The clinical diagnosis was cytologically confirmed in 92 per cent of these cases.

Carcinoma in Situ↗
PubMed1978

Carcinoembryonic antigen in serum, urine and cells of patients with bladder carcinoma.

A raised level of CEA-like substance has been demonstrated by radioimmunoassay in the urine of patients with bladder carcinoma, in concentrations which increase with a more advanced stage, and in serum of patients with advanced disease. In a 2-year follow-up of patients receiving chemotherapy, a correlation of raised urinary CEA to local recurrence was seen, as well as rising and high serum values with metastases. In the patients who responded to treatment, CEA values became normal. CEA was also located in carcinoma cells from bladder washings in 24--61% of the cases. Combined studies of CEA in serum, urine and cells may be used to study the biology of the tumour and perhpas also in the monitoring of patients with urothelial carcinoma.

Carcinoembryonic Antigen↗
PubMed1978

Radiation treatment of urinary bladder carcinoma.

A series of 602 patients with verified urinary bladder cancer have been treated with full irradiation in the period 1957--1970. As expected, the survival rate decreased with increasing stage of the tumour. Another group was randomized and treated according to either of two fractionation schemes. This trial started in 1971 and shows that there is increased survival and tumour clearance rate with superfractionation.

Aged↗
PubMed1978

Bladder carcinoma treated by preoperative radiotherapy followed by cystectomy.

In 1969 a clinical trial was started where patients with bladder carcinoma stage T2 and grade 3 were subjected to preoperative radiotherapy followed by cystectomy. The survival rate in this series was higher than in a previous series of comparable patients who were given full irradiation without cystectomy.

Cobalt Radioisotopes↗
PubMed1978

Orgotein (superoxide dismutase): a drug for the amelioration of radiation-induced side effects. A double-blind, placebo-controlled study in patients with bladder tumours.

Orgotein, the drug version of Cu-Zn superoxide dismutases is a new and safe anti-inflammatory agent. Animal experiments have shown that it does not interfere with the tumourolytic effects of radiation or chemotherapy. A double-blind, placebo-controlled study has demonstrated that orgotein injected after each daily irradiation session can be used safely and effectively to ameliorate or prevent the side effects due to high-energy radiation therapy (8,400 or 6,400 rads) of bladder tumours. Orgotein significantly reduced the signs and symptoms both in the bladder and the bowel, indicating that it provides a therapeutic regimen for control of these side effects, which to date could only be treated symptomatically.

Clinical Trials as Topic↗
PubMed1978

Chemotherapy in bladder carcinoma.

In a series of patients with recurrent bladder carcinoma, treatment with various cytostatic drugs was generally unsatisfactory in cases of infiltrating carcinoma. Better results were achieved using instillation of Thiotepa for bladder papillomatosis and by instillation of Adriamycin for carcinoma in situ.

Antineoplastic Agents↗
PubMed1978

Clinical experimental randomized study of 2.6-cis-diphenylhexamethylcyclotetrasiloxane and estramustine-17-phosphate in the treatment of prostatic carcinoma.

Patients with poorly differentiated prostatic carcinoma and skeletal metastases were randomized to treatment with 2.6-cis-diphenylhexamethylcyclotetrasiloxane (2.6-cis) and estramustine-17-phosphate (estramustine). Parallel with the clinical study a group of non-randomized patients were treated with 2.6-cis. Cytological regression of the tumor could be registered in half of the estramustine group but not in the 2.6-cis group. There were no drug-related changes in blood chemistry, kidney function tests, hematology or liver enzymes. There was in increase in acid and alkaline phosphatase in both groups but more pronounced in the 2.6-cis group. In both groups follicle-stimulating and luteinizing hormone values were depressed. Testicular and penis atrophy was observed in the 2.6-cis group. Relief of pain and marked improvement of conditions occurred in the majority of the cases in both groups. In general, no tumor regression was observed during administration of 300 mg. 2.6-cis daily for at least 3 months. Some tumor regression was noted during 600 mg. estramustine therapy daily.

Aged↗
PubMed1977

Estramustine phosphate therapy in carcinoma of the prostate.

Estramustine phosphate, a nor nitrogen mustard derivative of estradiol 17-beta-phosphate, was introduced in the treatment of prostatic carcinoma in 1966. Until March 1975, 466 patients have been reported on this treatment in open clinical trials: 82% of the patients were in stage IV. In 402 patients, nonresponsive to previous estrogen therapy, signigicant improvement occurred in 55%. In 64 previously untreated patients there was a favourable response in 83%. Side-effects were mainly bone marrow suppression. liver disturbance, thrombophlebitis following intravenous injection, and gastrointestinal troubles, mainly following oral administration. A prospective, randomized study comparing oral estramustine phosphate and conventional estrogen therapy in carcinoma of the prostate is in progress.

Administration, Oral↗
PubMed1977

Effect of bleomycin on peripheral lymphocytes.

Five patients with carcinoma of the penis receiving radiation therapy and injections of Bleomycin were examined to determine whether Bleomycin affects the peripheral pool of lymphoid cells. Total lymphocyte counts were not decreased, but transient reduction of the frequency of thymus-dependent cells occurred in 3 patients. The responses of the lymphocytes to phytomitogens and PPD were temporarily decreased these 3 patients. In 2 subjects the phytomitogen reactivity of the lymphocytes was improved after treatment.

Adult↗